Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Bio-Techne Corporation (TECH) — XLV Health Care · S&P 500 Profile |Bio-Techne公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Bio-Techne Corporation (TECH) — Business, History & S&P 500 Profile | Bio-Techne公司介紹

Bio-Techne Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #484 · Bio-Techne公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 5, 2026
Financials: FY2026
MARKET CAP
$11.43B
Nov 5, 2026
S&P 500 WEIGHT
0.02%
Rank #484 · Nov 5, 2026
SECTOR RANK
#57
Health Care · Nov 5, 2026
S&P 500 RANK
#484
0.02% · Nov 5, 2026

SNAPSHOT

TickerTECH
CompanyBio-Techne Corporation
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#484 · 0.02% (Nov 5, 2026)
Sector rank#57 of 60 in Health Care (Nov 5, 2026)
HeadquartersMinneapolis, Minnesota
Founded1976
CEOKim Kelderman (President and Chief Executive Officer)
Employees~3,000 (as of Jun 30, 2026)
Market cap$11.43B (Nov 5, 2026)
SEC filingsEDGAR — CIK 842023

WHAT IT DOES

Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets. Its Protein Sciences segment supplies the proteins, antibodies, immunoassays and analytical instruments that laboratories use every day, while its Diagnostics and Spatial Biology segment sells regulated diagnostic controls and assays and tissue-based spatial analysis platforms; customers are pharmaceutical and biotechnology companies, academic and government laboratories, diagnostic manufacturers and clinical laboratories. Headquartered in Minneapolis with about 3,000 employees, Bio-Techne has grown largely by acquiring specialist brands and folding them into a single commercial platform. That independent trajectory is now set to end: under the merger agreement signed on June 25, 2026, Merck KGaA would acquire Bio-Techne for $73.00 per share in cash and operate it as a wholly owned subsidiary, which would end Bio-Techne's standalone listing if the merger completes.

BUSINESS SEGMENTS

Protein SciencesA leading developer and manufacturer of high-quality biological reagents, including proteins, antibodies and immunoassays, used in life science research, diagnostics and cell and gene therapy, plus proteomic analytical tools for protein analysis, automated western blotting and multiplexed ELISA workflows (brands include R&D Systems, Novus Biologicals and ProteinSimple). FY2026 segment net sales were $874.6M.
Diagnostics and Spatial BiologyDevelops and manufactures diagnostic products, including controls, calibrators and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridisation assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications (brands include Advanced Cell Diagnostics and Lunaphore). FY2026 segment net sales were $336.4M.
Segment net sales total $1,211.0M; other revenue $5.4M less intersegment eliminations $1.4M reconciles to consolidated net sales $1,215.0M (FY2026 10-K segment note).

HISTORY

YearMilestone
1976Founded by Roger C. Lucas in Minneapolis, Minnesota, as Research and Diagnostic Systems, Inc., a maker of hematology controls and calibrators that grew into a broad supplier of biological reagents.
1985Merged into Techne Corporation and became a public company; the group operated under the Techne Corporation name for the following three decades.
2014Changed its name from Techne Corporation to Bio-Techne in November 2014 and embarked on an acquisition-led expansion, buying Novus Biologicals and ProteinSimple the same year.
2018Acquired Exosome Diagnostics for $250 million plus up to $325 million in milestone payments, expanding the diagnostics business into liquid biopsy and exosome-based testing.
2026On June 25, 2026, agreed to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in cash; the FY2026 Form 10-K states the merger is expected to close by late 2026 or early 2027, subject to regulatory and shareholder approvals.

COMPETITIVE POSITION

  • Thermo Fisher Scientific Inc. — the largest life science tools supplier, competing across reagents, instruments and diagnostics.
  • Danaher Corporation — competes through its life sciences and diagnostics platforms, including antibody and reagents businesses.
  • Merck KGaA (MilliporeSigma) — competes in research reagents and bioprocessing, and is simultaneously Bio-Techne's agreed acquirer.
  • Becton, Dickinson and Company (BD) — competes in biosciences reagents, instruments and clinical diagnostics.

FINANCIAL SNAPSHOT

Total revenue$1.22B (FY2026 revenue)
Operating income$251.9M (FY2026 operating income)
Net income$181.9M (FY2026 net income)
Diluted EPS$1.16 (FY2026 diluted EPS)
Source: Bio-Techne Corporation fiscal 2026 Form 10-K (period ended June 30, 2026; filed August 24, 2026). Exact figures: total revenue $1,215.0M; operating income $251.9M; net earnings $181.9M; diluted EPS $1.16. Employees: approximately 3,000 full-time and part-time employees as of June 30, 2026 (about 2,200 in the U.S. and 800 outside the U.S.), per the Form 10-K human capital disclosure. The Form 10-K also discloses a pending merger agreement with Merck KGaA dated June 25, 2026.

KEY RISKS

  • Merger completion risk: the Merck KGaA transaction requires regulatory approvals (shareholders approved the merger on September 23, 2026), restricts how Bio-Techne can operate while pending, and carries a termination fee if it fails, so the shares trade on deal completion rather than fundamentals alone.
  • Demand depends on pharmaceutical and biotechnology R&D spending and on academic and government research funding, which can be cut or deferred in funding downturns.
  • International exposure is material — FY2026 sales included $294.2M in EMEA excluding the UK and $104.1M in China — leaving results exposed to export controls, tariffs and geopolitical friction.
  • Acquisition-led growth brings integration, culture and goodwill risks, and past deals leave the balance sheet carrying substantial acquired intangible assets.

WHY IT MATTERS FOR THE S&P 500

Bio-Techne is a small-weight Health Care constituent: rank #484 by weight at 0.02% as of Nov 5, 2026, and #57 in Health Care. It gives the index a specialised life science tools maker, although its agreed acquisition by Merck KGaA would remove it as a standalone constituent if the merger completes.

SOURCES & METHODOLOGY

Financials, segments, headquartersBio-Techne Corporation fiscal 2026 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$11.43B (Slickcharts, Nov 5, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

TECH

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號TECH
公司Bio-Techne Corporation(Bio-Techne)
GICS 板塊/行業健康護理(XLV)/生命科學工具及服務
標普500排名(按權重)#484 · 0.02%(Nov 5, 2026)
板塊內排名健康護理板塊 #57(共 60 家)(Nov 5, 2026)
總部美國明尼蘇達州明尼阿波利斯
成立1976年
執行長Kim Kelderman(總裁兼行政總裁)
員工約 3,000 人(截至 2026 年 6 月 30 日)
市值$11.43B(Nov 5, 2026)
SEC 申報EDGAR — CIK 842023

業務概覽

Bio-Techne Corporation 開發、製造及銷售供研究、診斷及生物加工市場使用的生命科學試劑、儀器及服務。其蛋白質科學分部供應實驗室日常使用的蛋白質、抗體、免疫分析試劑及分析儀器;診斷及空間生物學分部則銷售受監管的診斷對照品與檢測,以及組織空間分析平台;客戶包括製藥及生物科技公司、學術及政府實驗室、診斷產品製造商及臨床實驗室。 公司總部位於明尼阿波利斯,僱員約 3,000 人,主要透過收購專門品牌並將其併入單一商業平台而增長。這條獨立發展之路現正走向終點:根據 2026 年 6 月 25 日簽署的合併協議,Merck KGaA 將以每股 73.00 美元現金收購 Bio-Techne,並將其作為全資附屬公司營運;若合併完成,Bio-Techne 的獨立上市地位將告結束。

業務板塊

蛋白質科學業務領先的優質生物試劑開發及製造商,產品包括蛋白質、抗體及免疫分析試劑,用於生命科學研究、診斷及細胞與基因治療,並提供用於蛋白質分析、自動化西方墨點法及多重 ELISA 工作流程的蛋白質組學分析工具(品牌包括 R&D Systems、Novus Biologicals 及 ProteinSimple)。2026 財年分部淨銷售額為 8.746 億美元。
診斷及空間生物學業務開發及製造診斷產品,包括供受監管診斷市場使用的對照品、校準品及診斷檢測,以及用於空間基因組學及組織活檢分析的先進組織原位雜交檢測與儀器,和供研究及臨床應用的遺傳學與腫瘤學試劑盒(品牌包括 Advanced Cell Diagnostics 及 Lunaphore)。2026 財年分部淨銷售額為 3.364 億美元。
分部淨銷售額合計 12.110 億美元;其他收入 0.054 億美元減分部間抵銷 0.014 億美元,調節至綜合淨銷售額 12.150 億美元(2026 財年 10-K 分部附註)。

歷史

年份里程碑
1976由 Roger C. Lucas 在明尼蘇達州明尼阿波利斯創立,初名 Research and Diagnostic Systems, Inc.,最初製造血液學對照品及校準品,其後發展為全面的生物試劑供應商。
1985併入 Techne Corporation 並成為上市公司;集團其後三十年以 Techne Corporation 之名營運。
2014於 2014 年 11 月由 Techne Corporation 更名為 Bio-Techne,並展開以收購帶動的擴張,同年收購 Novus Biologicals 及 ProteinSimple。
2018以 2.50 億美元另加最高 3.25 億美元里程碑付款收購 Exosome Diagnostics,將診斷業務擴展至液體活檢及外泌體檢測。
2026於 2026 年 6 月 25 日同意由德國達姆施塔特的 Merck KGaA 以每股 73.00 美元現金收購;2026 財年 Form 10-K 表示,合併預計於 2026 年底或 2027 年初完成,尚待監管及股東批准。

競爭地位

  • Thermo Fisher Scientific Inc. — 最大的生命科學工具供應商,於試劑、儀器及診斷領域全面競爭。
  • Danaher Corporation — 透過其生命科學及診斷平台競爭,包括抗體及試劑業務。
  • Merck KGaA(MilliporeSigma)— 於研究試劑及生物加工領域競爭,同時亦為 Bio-Techne 已協議的收購方。
  • Becton, Dickinson and Company(BD)— 於生物科學試劑、儀器及臨床診斷領域競爭。

財務快照

總收入12.15 億美元(2026 財年收入)
營業利潤2.52 億美元(2026 財年營業利潤)
淨利潤1.82 億美元(2026 財年淨利潤)
稀釋 EPS1.16 美元(2026 財年稀釋 EPS)
資料來源:Bio-Techne Corporation 2026 財年 Form 10-K(期間截至 2026 年 6 月 30 日;2026 年 8 月 24 日提交)。準確數字:總收入 12.150 億美元;營業利潤 2.519 億美元;淨利潤 1.819 億美元;攤薄每股盈利 1.16 美元。僱員:截至 2026 年 6 月 30 日,約 3,000 名全職及兼職僱員(約 2,200 人位於美國、800 人位於美國以外),載於 Form 10-K 人力資本披露。Form 10-K 亦披露與 Merck KGaA 於 2026 年 6 月 25 日訂立的待完成合併協議。

主要風險

  • 合併完成風險:Merck KGaA 交易須獲監管批准(股東已於 2026 年 9 月 23 日批准合併),待完成期間 Bio-Techne 的營運受到限制,交易若告吹亦涉及終止費,因此股價表現取決於交易能否完成,而非單由基本因素決定。
  • 需求取決於製藥及生物科技研發開支,以及學術與政府研究經費;經費緊縮時,相關開支可被削減或押後。
  • 國際敞口龐大 — 2026 財年銷售額包括歐洲、中東及非洲(英國除外)2.942 億美元及中國 1.041 億美元 — 業績容易受出口管制、關稅及地緣政治摩擦影響。
  • 以收購帶動的增長帶來整合、文化及商譽風險,過往交易亦令資產負債表承載大量收購所得的無形資產。

對標普500的重要性

Bio-Techne 是權重較小的健康護理板塊成分股:截至 2026 年 11 月 5 日,按權重排名第 484 位,權重 0.02%,在健康護理板塊中排名第 57 位。它為指數帶來一家專門的生命科學工具製造商,惟其已協議由 Merck KGaA 收購,若合併完成,將不再是獨立成分股。

來源與方法

財務、板塊、總部財務數據:Bio-Techne Corporation 2026 財年 Form 10-K,經 SEC EDGAR 取得(詳見財務摘要附註);總部、行政總裁及歷史資料來自 Form 10-K 及 Wikipedia 公司簡介
指數權重與排名Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$11.43B(Slickcharts,Nov 5, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

TECH

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · TECH
Data as of Nov 5, 2026 · Financials FY2026 (10-K) · Market data Nov 2026
Previous · Universal Health Services, Inc. (UHS) — XLV Health Care · S&P 500 Profile |Universal Health Services公司介紹Next · Pentair plc (PNR) — XLI Industrials · S&P 500 Profile |濱特爾公司介紹

Entered 2026-11-04 14:43 · updated 2026-11-15 00:06 · rev 9